Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410878 | 0.91 | MAP4K4 (0.52) | MAP4K4SLC6A9HDAC1HDAC2HDAC3 | |
| SCHEMBL15587796 | 0.90 | NPSR1 (0.59) | MAP4K4SLC6A9HDAC1HDAC2HDAC3 | |
| SCHEMBL17896325 | 0.86 | MAP4K4 (0.48) | MAP4K4SLC6A9HDAC1HDAC2HDAC3 | |
| SCHEMBL19015883 | 0.86 | SMN1; SMN2 (0.50) | MAP4K4SLC6A9HDAC1HDAC2HDAC3 | |
| SCHEMBL28872344 | 0.84 | SMN1; SMN2 (0.56) | MAP4K4HDAC1HDAC2HDAC3MAPK10 | |
| SCHEMBL2245967 | 0.83 | NPSR1 (0.62) | SLC6A9HDAC1HDAC2HDAC3LMNA | |
| SCHEMBL8408804 | 0.78 | F10 (0.53) | — | |
| SCHEMBL21923085 | 0.76 | PIP5K1C (0.54) | MAP4K4MAPK10MAPK8MAPK14MEN1 | |
| SCHEMBL15886294 | 0.76 | BACE1 (0.53) | HDAC1HDAC2HDAC3MAPK10MAPK8 | |
| SCHEMBL9940282 | 0.76 | HPGD (0.69) | HDAC1HDAC2HDAC3MAPK10MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | MAP4K4 2964/4885SLC6A9 4523/4885HDAC1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.